A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophreniaJean Pierre Lindenmayer
Manhattan Psychiatric Center, Psychopharmacology Research Unit, New York, NY 10035, USA
J Clin Psychiatry 68:368-79. 2007
....
- Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study
Jean Pierre Lindenmayer
Psychopharmacology Research Unit, Manhattan Psychiatric Center, Wards Island, NY 10035, USA
J Clin Psychiatry 63:931-5. 2002
....
Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophreniaJean Pierre Lindenmayer
Department of Psychiatry, New York University School of Medicine, New York, NY, USA
Clin Schizophr Relat Psychoses 5:185-92. 2012
....
- Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
Jean Pierre Lindenmayer
Nathan Kline Institute fo Psychiatric Research, New York, NY 10035, USA
Am J Psychiatry 160:290-6. 2003
....
- Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics
Jean Pierre Lindenmayer
Manhattan Psychiatric Center, New York University School of Medicine, New York, NY 10035, USA
J Clin Psychiatry 65:1084-9. 2004
..The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications...
- A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder
Jean Pierre Lindenmayer
Manhattan Psychiatric Center, Psychopharmacology Research Program, New York, NY, USA
J Clin Psychopharmacol 31:160-8. 2011
..In conclusion, quetiapine at 1200 mg/d, although reasonably tolerated, did not confer any advantages over quetiapine at 600 mg/d among patients who had failed to demonstrate an adequate response to a prospective 4-week trial of 600 mg/d...
- An excitement subscale of the Positive and Negative Syndrome Scale
Jean Pierre Lindenmayer
Department of Psychiatry, New York University School of Medicine, and Manhattan Psychiatric Center, Wards Island Complex, New York, NY, USA
Schizophr Res 68:331-7. 2004
....
- Outcome evaluation of a structured educational wellness program in patients with severe mental illness
Jean Pierre Lindenmayer
Manhattan Psychiatric Center, Department of Psychiatry, New York University School of Medicine, Manhattan, New York, New York, USA
J Clin Psychiatry 70:1385-96. 2009
....
Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapyJoseph I Friedman
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
Neuropsychopharmacology 36:1289-95. 2011
..However, given the lack of evidence to guide clinicians and patients when clozapine does not work well, more controlled trials of innovative strategies are warranted...
- The InterSePT scale for suicidal thinking reliability and validity
J P Lindenmayer
New York University School of Medicine, New York, NY, USA
Schizophr Res 63:161-70. 2003
..We report the psychometric characteristics of this new scale based on two studies...
- A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness
Jean Pierre Lindenmayer
Manhattan Psychiatric Center, 600 East 125th St, Wards Island, NY 10035, USA
Psychiatr Serv 59:241-7. 2008
..This study evaluated the feasibility and efficacy of a cognitive remediation program in improving cognitive and work functioning for intermediate- to long-stay psychiatric inpatients...
- Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone
Jean Pierre Lindenmayer
New York University Medical Center, New York, USA
Int Clin Psychopharmacol 20:213-21. 2005
..30; endpoint = 7.70; P<0.0001 versus baseline). These findings may positively affect patient and clinician attitudes towards long-term therapy with long-acting injectable risperidone...
- A cognitive, behaviorally based program for patients with persistent mental illness and a history of aggression, crime, or both: structure and correlates of completers of the program
Kathy Yates
New York University School of Medicine and Manhattan Psychiatric Center, Ward s Island Complex, NY 10035, USA
J Am Acad Psychiatry Law 33:214-22. 2005
..In comparison with the 91 who did not complete the program, those who did were less cognitively impaired and less impulsive. We present a new, intensive treatment program and define the predictors of successful completion of the program...
- Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review
Carlos Saavedra-Velez
Department of Psychiatry, New York University Medical Center, New York, NY, USA
J Clin Psychiatry 70:104-12. 2009
....
- Relationship between metabolic syndrome and cognition in patients with schizophrenia
Jean Pierre Lindenmayer
Manhattan Psychiatric Center, Wards Island, NY, United States New York University, New York, NY, United States Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, United States Electronic address
Schizophr Res 142:171-6. 2012
..We hypothesized that patients with MetS would be associated with more impaired cognitive performance...
- The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study
Jean Pierre Lindenmayer
Manhattan Psychiatric Center Nathan Kline Institute for Psychiatric Research, New York University, New York, NY, USA
Psychopharmacol Bull 41:11-35. 2008
..This study aimed to demonstrate efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) versus placebo in patients with acute schizophrenia...
- Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder
Jean Pierre Lindenmayer
Manhattan Psychiatric Center, New York University of Medicine, New York, NY, USA
Eur Neuropsychopharmacol 17:138-44. 2007
..It is concluded that treatment with long-acting injectable risperidone for 1 year or longer appeared to be safe and well tolerated in patients with schizophrenia or schizoaffective disorder...
- Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale
Jean Pierre Lindenmayer
Manhattan Psychiatric Center, New York University of Medicine, New York, NY, USA
Psychopathology 41:264-70. 2008
....
- Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response
Jean Pierre Lindenmayer
New York University School of Medicine, New York, N Y 10035, USA
J Clin Psychiatry 70:990-6. 2009
..To examine the impact of medication nonadherence on treatment outcome in schizophrenia and potential risk factors for nonadherence...
- Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review
Rachel Neuhut
Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
J Child Adolesc Psychopharmacol 19:415-22. 2009
..The purpose of this report is to examine the published cases of NMS in children and adolescents receiving atypical antipsychotic medication and review early warning symptoms, risk factors, and treatment in this population...
- Item response analysis of the Positive and Negative Syndrome Scale
Darcy A Santor
School of Psychology, University of Ottawa, Ottawa, Canada, and The Provincial Centre of Excellence for Child and Youth Mental Health, Ottawa, Ontario, Canada
BMC Psychiatry 7:66. 2007
....
- Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic
John M Kane
The Zucker Hillside Hospital, New York, NY 11004, USA
Am J Psychiatry 160:1125-32. 2003
..CONCLUSIONS: Long-acting injectable risperidone was efficacious and well tolerated and provides both clinicians and patients with a new mode of treatment that can improve the outcome of long-term therapy...
- Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
Bruce J Kinon
Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 28:392-400. 2008
....
- The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients
Larry Alphs
Schizophr Bull 30:577-86. 2004
..Because of the complexity of the design issues, a steering committee, suicide monitoring board, and publication committee were established to assist with their management...
- Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation
Jan Volavka
Schizophr Res 76:127-9. 2005
- Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder
Jan Volavka
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
Am J Psychiatry 159:255-62. 2002
....
- Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial
Marc Bourgeois
Psychopathology Research Laboratory, University of Bordeaux, 3 ter, Place de la Victoire, 33076 Bordeaux, France
Am J Psychiatry 161:1494-6. 2004
..The complex interactions and mediation effects of these clinical variables require careful monitoring...
- Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol
Jan Volavka
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
J Clin Psychopharmacol 24:225-8. 2004
..Clozapine appears to have superior antiaggresive effects in treatment-resistant patients; this superiority develops after the patient has been exposed to an adequate dose regimen...
- Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
Jean Pierre Lindenmayer
Nathan Kline Institute, Orangeburg, N Y, USA
J Clin Psychiatry 65:551-6. 2004
..We are exploring whether this expanded clinical efficacy can also be seen in patients with treatment-resistant schizophrenia...
- COMT158 polymorphism and hostility
Jan Volavka
Nathan Kline Institute, Orangeburg, New York 10982, USA
Am J Med Genet B Neuropsychiatr Genet 127:28-9. 2004
..The Met-Met homozygotes (N = 7) were found to have significantly higher levels of hostility than the other patients (N = 53). The hypothesis was thus supported. The finding should be replicated in a larger sample...
- Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol
Jan Volavka
Nathan Kline Institute, Orangeburg, NY 10982, USA
J Clin Psychiatry 65:57-61. 2004
....
- Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia
Robert M Bilder
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Biol Psychiatry 52:701-7. 2002
....
- Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
Robert M Bilder
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Am J Psychiatry 159:1018-28. 2002
....
- Antipsychotic-induced weight gain and therapeutic response: a differential association
Pal Czobor
Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
J Clin Psychopharmacol 22:244-51. 2002
..These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain...
- Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder
Karen A Nolan
Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
J Psychiatr Res 39:109-15. 2005
..These findings in chronic, treatment resistant inpatients support the view that positive symptoms may lead to aggression...
- Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment
Vincenzo De Luca
Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R 30, Toronto, Ont, Canada M5T 1R8
Pharmacol Res 51:381-4. 2005
..Our results suggest that the novel polymorphism may not play a major role in antipsychotic response...
- Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia
Daniel J Muller
Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Eur Neuropsychopharmacol 15:525-31. 2005
..8 to 7%. Our results further suggest that this effect is only attributable to Caucasians when compared to African-Americans. Moreover, our findings point to the role of intracellular mechanisms in antipsychotic response...
- Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder
Matthew J Hoptman
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
Psychiatry Res 140:133-45. 2005
..Larger left OFC gray matter volumes and larger OFC white matter volumes bilaterally were associated with greater levels of aggression. These findings are discussed in the context of potential iatrogenic effects...
- Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies
Leslie Citrome
Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
J Clin Psychiatry 66:1512-6. 2005
..The purpose of this article is to review the past and present dosing patterns of quetiapine for the treatment of schizophrenia...
- Improved long-term outcome with long-acting risperidone treatment of chronic schizophrenia with prior partial response
Jean-Pierre Lindenmayer
McLean Hospital
J Psychiatr Pract 12:55-7. 2006
- Clozapine augmentation with aripiprazole for negative symptoms
Laura A Clarke
J Clin Psychiatry 67:675-6. 2006
- Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients
Andrya M Crossman
J Clin Psychiatry 67:1158-9. 2006
- Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
Daniel E Casey
J Clin Psychiatry 65:4-18; quiz 19-20. 2004
- The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia
Daniel J Muller
Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R30, Toronto, Ont M5T 1R8, Canada
Neurosci Lett 379:81-9. 2005
..Weight changes do not seem to be associated with polymorphism of the SNAP-25 gene, however, replication in independent samples is warranted...
- Normal pressure hydrocephalus presenting as Othello syndrome: case presentation and review of the literature
Anna Yusim
Department of Psychiatry, New York University Medical Center, New York, NY 10128, USA
Am J Psychiatry 165:1119-25. 2008
- Efficacy of molindone in treatment-refractory agitated schizophrenia: three case reports
Michael Ciranni
J Clin Psychiatry 69:1018-9. 2008
- Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder
Matthew J Hoptman
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
J Neuropsychiatry Clin Neurosci 18:509-15. 2006
..The relationship between aggression and caudate volumes may be related to the iatrogenic effects of long-term treatment with typical antipsychotic agents or to a direct effect of schizophrenic processes on the caudate...
- Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients
Robert C Smith
Department of Psychiatry, New York University Medical School, Hewlett, NY 11557, USA
Int J Neuropsychopharmacol 8:183-94. 2005
....
- Measuring efficacy of polypharmacy in schizophrenic inpatients
Jean-Pierre Lindenmayer
J Clin Psychiatry 65:1148; author reply 1148. 2004
